Evidence map›Paper›PMID 42840974›Full record

ReviewFrontiers in immunology2026

Sangbeom Lee, Moonhae Kim, Yian Wang, Bryon Johnson, Ming You

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Sangbeom LeeCenter for Cancer Prevention, Houston Methodist Cancer Center, Houston Methodist Research Institute, Houston, TX, United States.
Moonhae KimDepartment of Kinesiology, Rice University, Houston, TX, United States.
Yian WangCenter for Cancer Prevention, Houston Methodist Cancer Center, Houston Methodist Research Institute, Houston, TX, United States.
Bryon JohnsonDivision of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, United States.
Ming YouCenter for Cancer Prevention, Houston Methodist Cancer Center, Houston Methodist Research Institute, Houston, TX, United States.

Funding

Transfer Application - R01 CA223804 - Chemoimmunoprevention of EGFR-Driven Non-Small Cell Lung CancerR01CA223804 · NCI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI WANG, LI LILY, YOU, MING · 2018 to 2022
$3.3M
Inhibition of Oral Tumorigenesis by Antitumor BR01CA205633 · NCI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI HU, MING, WONG, STUART J · 2017 to 2022
$2.6M
Chemoprevention of lung cancer by targeting lonidamine to mitochondriaR01CA232433 · NCI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI KALYANARAMAN, BALARAMAN, KRESTY, LAURA A · 2019 to 2023
$2.0M
Targeting phenethyl isothiocyanate to mitochondria in lung carcinogenesisR01CA280746 · NCI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI MING YOU, Jacek M Zielonka · 2024 to 2026
$1.9M
NCI NIH HHS R01 CA205633NCI NIH HHS R01 CA223804NCI NIH HHS R01 CA232433NCI NIH HHS R01 CA280746NIH HHS 75N93024F00002
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Cancer VaccinesNeoplasmsVaccinationAnimalsAntigens, NeoplasmHumansImmunotherapyNeoplasm MetastasisAntigens, NeoplasmCancer Vaccinesbiomaterials and drug deliverydendritic cell cross-primingimmunogenic cell deathin situ vaccinationintratumoral immunotherapyradiotherapy fractionation

Identifiers

PMID42840974
PMCPMC13640006

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.